Popular, Pharmaceutical Industry, UK

UK and U.S. economic prosperity deal takes effect – Key takeaways

Hogan Lovells on 7/9/2025

The Economic Prosperity Deal agreed between the UK and the U.S. sets out high level trade commitments and areas for further negotiation between the two countries. A series of implementing measures are described in Executive...more

Will Labour’s policy prescription create a stronger UK life sciences sector?

A&O Shearman on 3/27/2025

The UK government plans to turbocharge the life sciences sector using policy levers to enhance research and development, innovation hubs, and private fundraising. In this piece, Michael Bloch explores how refinements to...more

Antitrust and Competition Life Sciences Year in Review 2024

Goodwin on 2/21/2025

The last year (and particularly the last few months) of the Biden Administration brought a flurry of activity from the Federal Trade Commission (FTC) in the life sciences space, continuing a yearslong pattern of close...more

European Antitrust Bimonthly Bulletin – July/August 2024

Wilson Sonsini Goodrich & Rosati on 9/6/2024

The "European Antitrust Bimonthly Bulletin” breaks down the major antitrust developments in Europe during the past two months into concise and actionable takeaways. ...more

A Look Ahead in Life Sciences: What We Are Tracking in Q1 2024 and Beyond

Goodwin on 1/4/2024

As the life sciences, medtech, and diagnostic industries continue to expand and grow increasingly complex, so does the legal, regulatory, and compliance landscape. To help companies and investors navigate the many evolving...more

Transatlantic M&A bull run set for comeback

White & Case LLP on 9/15/2023

Encouraged by the relative strength of the dollar and improving financing conditions, US bidders are snapping up European assets - Transatlantic M&A was enjoying record-high activity before the war in Ukraine sparked...more

Global healthcare M&A delivers strong performance

White & Case LLP on 1/25/2023

Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022 - Following a ground-breaking year for dealmaking in 2021, global healthcare M&A remained robust in 2022,...more

Global Trends and Opportunities in Life Sciences Real Estate – Spotlighting the U.S. and the UK

Goodwin on 9/30/2020

An aging global population, a once-in-a-century pandemic and the continued convergence of scientific breakthroughs like cell and gene therapies and artificial intelligence are among just a few of the key factors that continue...more

Healthcare AI Deals a Tonic for Private Equity Investors

Latham & Watkins LLP on 9/23/2020

Healthcare artificial intelligence is a promising sector for PE investors that requires careful navigation, particularly given divergent regulatory approaches. PE funds invested more than US$14 billion in healthcare...more

Top 10 International Anti-Corruption Developments For July 2020

Morrison & Foerster LLP on 8/13/2020

In order to provide an overview for busy in-house counsel and compliance professionals, we summarize below some of the most important international anti-corruption developments from the past month, with links to primary...more

Top 10 International Anti-Corruption Developments For June 2020

Morrison & Foerster LLP on 7/17/2020

In order to provide an overview for busy in-house counsel and compliance professionals, we summarize below some of the most important international anti-corruption developments from the past month, with links to primary...more

NHS medicine and device suppliers urged to carry out supply chain coronavirus risk assessment

Hogan Lovells on 3/3/2020

At the end of last week, the World Health Organisation (WHO) upgraded the global risk assessment of the novel coronavirus to "very high." This comes shortly after the United Kingdom saw its first fatality as a result of...more

Celltrion to Launch REMSIMA SC (infliximab) in Europe in March, 2020

Goodwin on 1/31/2020

Multiple sources are reporting that Celltrion is planning to roll out REMSIMA SC, its subcutaneous infliximab biosimilar of Johnson & Johnson’s autoimmune disease treatment REMICADE, in Europe in the first quarter of 2020,...more

Cross-Border Investigations Update - September 2019

Skadden, Arps, Slate, Meagher & Flom LLP on 10/3/2019

This issue of Skadden’s semiannual Cross-Border Investigations Update takes a close look at recent cases, regulatory activity and other key developments, including a review of the first year of GDPR enforcement, analysis of...more

View from the Horizon: Artificial Intelligence and Cannabusiness in London

Hogan Lovells on 6/14/2019

On May 16 the second edition of our new global series, Life Sciences and Health Care Horizons, took place in London featuring two panel discussions that focused on the challenges and opportunities in two of the sector’s...more

Brexit: the impact on supplementary protection certificates (SPCs)

Hogan Lovells on 3/18/2019

On 6 February 2019 the House of Commons and House of Lords approved The Patents (Amendment) (EU Exit) Regulations 2018 (Patent SI), which, if it is signed into law, will come into force on Brexit day (i.e. 29 March 2019 or...more

Amgen and Sandoz Launch Biosimilars in Europe

Goodwin on 10/17/2018

Amgen has announced that its adalimumab biosimilar AMGEVITA launched yesterday in European markets. This is Amgen’s first “inflammation” biosimilar to launch in Europe, and its second biosimilar to launch in Europe overall. ...more

UK publishes paper on Brexit and medicines regulation

Hogan Lovells on 11/22/2017

On the same day as the European Council voted to move the European Medicines Agency (EMA) from London to Amsterdam, the UK Parliament issued a briefing paper on Brexit and medicines regulation. ...more

Brexit – the end of parallel imports from the UK?

Hogan Lovells on 4/20/2017

The United Kingdom's unprecedented vote to leave the EU will undoubtedly cause a broad range of legal issues in the future. This post focuses on the consequences of Brexit on parallel imports - a field of significant...more

Alert: Pfizer and Flynn Pharma Fined £90 Million for Charging “Excessive Prices” for Epilepsy Medicine

Cooley LLP on 12/15/2016

The UK Competition and Markets Authority (the CMA) announced on 7 December that it had fined pharmaceutical manufacturer Pfizer and its UK distributor Flynn Pharma a total of £90 million. According to the CMA, the companies...more

MoFo IP Newsletter - November 2016

Morrison & Foerster LLP on 11/29/2016

FDA (Finally!) Issues New Regulations to Clarify Pharmaceutical Patent Litigation: How to Use Patent “Use Codes” - October 6, 2016, the FDA issued a final rule implementing certain provisions of the Medicare...more

Freedom to Utilize Genetic Resources? The Nagoya Protocol Two Years Later

WilmerHale on 10/13/2016

Two years ago today, the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization to the Convention on Biological Diversity (“Protocol”) entered into international...more

Brexit Update: What’s Next for the Global Marketplace

McDermott Will & Schulte on 7/8/2016

In Depth - UK Withdrawal Process - The United Kingdom will continue to be an EU member until procedures are completed for exiting the European Union, which is likely to be a long process. Under EU Treaty rules,...more

Additional IP Considerations in Light of Brexit

Morgan Lewis on 7/7/2016

Pharmaceutical and agricultural companies in particular should consider the effect of Brexit on their European patent portfolios. Supplementary Protection Certificates (SPCs) are governed by EU regulations and are thus...more

UK High Court confirms jurisdiction to grant cross-border declaration of non-infringement

Mintz - Intellectual Property Viewpoints on 6/12/2014

In Actavis Group HF v. Eli Lilly & Co. the UK High Court has granted a declaration of non-infringement in the UK, France, Italy and Spain. A jurisdictional challenge in relation to the French, Italian and Spanish...more

Today's Popular Updates › Pharmaceutical Industry › United Kingdom

"My best business intelligence, in one easy email…"